ICE Bioscience develops acquired drug-resistant cancer cell lines through continuous or stepwise drug exposure. Our cell line–based approach emphasizes experimental control and reproducibility, supporting mechanism studies, resistance profiling, and combination strategy exploration in a research setting.
We generate resistant sublines from defined parental cancer cell lines by sustained selection with specified compounds or payloads. This enables stable resistance phenotypes that are straightforward to validate and practical for iterative discovery workflows.
RI represents the fold increase in IC50 for the resistant subline relative to the parental line.
This quantitative anchor helps communicate resistance magnitude and supports consistent benchmarking across experiments and programs.
Resistant sublines developed against payload classes such as topoisomerase I inhibitors or tubulin inhibitors, enabling cross-resistance evaluation and strategy development for ADC programs.
Resistant sublines induced by prolonged exposure to RAS inhibitors to support pathway adaptation studies and rational combination exploration.
Add-ons may include transporter overexpression checks such as ABCG2 or ABCB1, target/pathway markers, and transcriptomic comparison between parental and resistant lines.
Set up drug selection using continuous exposure or stepwise escalation to establish resistant populations.
Run sequential viability assays; quantify IC50 shift and calculate Resistance Index (RI) versus parental cells.
Validate phenotype stability across passages; confirm resistance is maintained under defined culture conditions.
Compare parental vs resistant growth characteristics; evaluate doubling time and saturation density trends.
Mechanism-focused readouts available, including RNA-seq and WES, to support resistance driver hypothesis building.
Generate edited cell pools or clones aligned to the target hypothesis, using project-defined editing strategy.
Validate editing outcome and phenotype; confirm functional impact using assays relevant to the intended mechanism.
Confirm phenotype persistence across passages and verify consistency under standardized culture conditions.
Share your compound (or payload), preferred parental cell line, and desired resistance criteria. We will propose a selection strategy and a validation plan aligned with your research goals.
We value your inquiries and are here to provide you with tailored solutions for your drug discovery and development needs. Whether you have questions, require more information, or are interested in discussing potential collaborations, our team of experts is just a message away.
Feel free to reach out to us.
Address: Bldg 16, Yd 18, Kechuang 13th St, Etown, Tongzhou Dist, Beijing, 100176, China
Email: marketing@ice-biosci.com
Tel：+86-10-67809840
